Navigation Links
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease
Date:11/26/2008

SAN DIEGO, Nov. 26 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. The trial did not demonstrate an appreciable difference between patients treated with CERE-120 versus those in the control group. Both groups showed an approximate 7 point improvement in the protocol-defined primary endpoint (Unified Parkinson's Disease Rating Scale- motor off score at 12 months), relative to a mean at baseline of approximately 39 points. Both groups had a substantial number of patients who demonstrated a meaningful clinical improvement from baseline. CERE-120 appeared to be safe and well tolerated.

"On behalf of everyone at Ceregene, I would like to personally express my gratitude to all the patients, physicians and staff who participated in this study. We share their disappointment. We also offer our heartfelt appreciation to the many talented and dedicated employees at Ceregene who continue to work extremely hard on this and Ceregene's other programs," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "We continue to believe in the multiple opportunities in our pipeline that target a range of serious neurodegenerative and ocular diseases."

"The medical research community has for several decades attempted to use the unique healing properties of neurotrophic factors to treat serious neurodegenerative diseases, and Ceregene's use of gene therapy as an essential enabling technology to translate this idea into an effective human therapeutic has consistently generated strong empirical support," stated Raymond T. Bartus, Ph.D., Ceregene's executive vice president and chief scientific officer. "Thus, we are stunned by the results of this trial and will continue to analyze the data in order to gain greater insight into the factors that may have contr
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
2. Ceregene Announces Two Key Additions to Leadership Team
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Gallus BioPharmaceuticals , ... and manufacturing organization (CMO) announced today that it ... oncology company focused on the development of innovative ... the anti-prostate specific membrane antigen (PSMA) monoclonal antibody ... Under the agreement the antibody will be produced ...
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
(Date:8/20/2014)... California (PRWEB) August 20, 2014 ... develop and apply the most complete climate and ... and demanding climate change issues. , Eight national ... forces with the National Center for Atmospheric Research, ... the new effort. Other participating national laboratories include ...
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... and beyond have been given a new Web-based tool ... interns among the graduates and students of Wisconsins universities ... brings together the career services offices at the University ... resources of the other four-year campuses of the UW ...
... , a health care software and services company, announced ... version 2.5. The updated product includes integration with FUSION ... billing workflow to run from a single, unified end-user ... create productivity improvements for the radiologist and technologist by ...
... days, Al Jacobs taught students about the power of doubling by talking ... and the pads doubled in area every day: How long would it ... cover a pond of 250,000 square feet? , ,Only 17 days, thanks ... 32 and so on, until on the 17th day, 131,072 square feet ...
Cached Biology Technology:New Web site makes recruiting from Wisconsin universities easier 2Merge eFilm announces release of FUSION RIS version 2.5 2Doubling the lily pads: Controlling the explosion in health care costs 2Doubling the lily pads: Controlling the explosion in health care costs 3
(Date:8/21/2014)... growing in near darkness use a previously unknown process ... research team led by a Penn State University scientist ... research aimed at improving plant growth, harvesting energy from ... occurring on Lake Erie and other lakes worldwide. A ... Science Express edition of the journal ...
(Date:8/21/2014)... eczema and other itchy, flaky maladies in humans has ... coral reefs and the extreme environments of arctic soils ... scientific journal PLOS Pathogens considers the diversity, ... Malassezia in light of new insights gained ... , University of Hawai,i at Mānoa scientist Anthony Amend ...
(Date:8/21/2014)... landmark study aimed at improving the food intake, health ... care homes is among three projects at the University ... from the Canadian Institutes of Health Research (CIHR). ... Health Sciences at Waterloo, and a Schlegel research chair ... years to investigate why many Canadians living in long-term ...
Breaking Biology News(10 mins):Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Grants will fund landmark aging research at Waterloo 2
... Using a carbon nanotube instead of traditional silicon, Cornell ... that hopefully will lead to much more efficient ways of ... on rooftops. The researchers fabricated, tested and measured a ... carbon nanotube. Reported online Sept. 11 in the journal ...
... of Texas at San Antonio (UTSA) has received a ... (NSF) to study nanomaterials and their biomedical applications. ... Education in Materials grant, is the second major NSF ... announced the receipt of $5 million to establish a ...
... diabetes, not only do waistlines matter to women, but so does ... a team of Swedish researchers was just published online in the ... of normal weight develop type 2 diabetes, despite not having any ... fat cells and the development of type 2 diabetes may give ...
Cached Biology News:Carbon nanotubes could make efficient solar cells 2UTSA Physics Department receives $2.7 million to study nanomaterials 2Size of fat cells and waist size predict type 2 diabetes in women 2
... Life Sciences provides cost effective cell culture ... or monoclonal antibodies. Quality at a reasonable ... you require research or commercial product, we ... methods such as roller bottles, hollow fiber, ...
... for hunting and analyzing the rare ... EST sequencing projects, microarrays, functional screenings ... well suited for the normalization of ... though, is specially developed for normalization ...
... Application: The Panorama Mouse/Rat Tissue Extract Protein ... expression in various tissue extracts. The expression ... detected using a protein specific antibody. When ... is visualized by a sensitive chemiluminescent or ...
... StabilGuard Choice Microsphere/Microarray Stabilizer is a ... Plus Stabilizer. This product is an ... a PBS buffer (phosphate buffered saline), pH ... a combination of 0.02% methylisothiazolone and 0.02% ...
Biology Products: